Review of NICE Technology Appraisal Guidance No.101; Docetaxel for the treatment of hormone refractory prostate cancer

TA101; Docetaxel for the treatment of hormone refractory prostate cancer was published in June 2009.  Due to the overlap with a current update to an existing clinical guideline, the Institute to re-look at the existing technology appraisal guidance and the possible scope for a review.

We believe that this topic would be better dealt with within the context of the clinical guideline. Consequently we propose that the recommendations from the original guidance be incorporated into the on-going update of CG58 ‘Prostate cancer: diagnosis and management’.

TA101 will remain in existence alongside the clinical guideline and will be moved to the static guidance list.  This proposal will have the consequence of preserving the funding direction that is linked to the technology appraisal.

In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which will help us decide the best way to update this guidance.  Please see appendix A for a full list of the organisations we have contacted. 

March 2012